Abstract
The text discusses the role of general practitioners (GPs) in the prevention and early diagnosis of melanoma, a type of skin cancer. It highlights the need for GPs to be able to recognize suspicious skin lesions and refer patients to specialist dermatology centers. However, many GPs lack comprehensive training in diagnosing melanoma. The text mentions that various training courses have been conducted for GPs, but their impact on clinical practice has been limited.
The “MelaMEd Programme” is an e-learning course developed by the Italian Melanoma Intergroup (IMI). The program aims to provide GPs with comprehensive knowledge of melanoma prevention, diagnosis, and treatment. It includes an e-learning section and a dedicated platform called MelaMEd platform, which offers a multimedia atlas of melanoma.
The objective of the study is to evaluate the impact of the MelaMEd programme on GPs’ diagnostic accuracy, knowledge of melanoma, and management of suspicious lesions. The methodology involves administering pre-training and post-training questionnaires to participants, assessing their diagnostic skills and evaluating the training course’s effectiveness.
The study aims to demonstrate the effectiveness of the MelaMEd programme in improving GPs’ ability to recognize and manage melanoma. It also seeks to identify areas for improvement and recommend interventions to enhance diagnostic accuracy. The results will be analyzed statistically using descriptive, univariate, and multivariate analysis methods.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health within the research line Appropriateness, outcomes, drug value and organizational models for the continuity of diagnostic-therapeutic pathways in oncology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study design complied with the Declaration of Helsinki ethical standards and was approved by the Ethics Committee at the Romagna Cancer Institute (ID: IRST100.37; IRST identifier codes: L4P3037, wfn.27L4). The study was approved by the Scientific Committee of the Italian Melanoma Intergroup (IMI).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
The anonymized dataset used in this study is available on request from the corresponding author.
